InvestorsHub Logo
Followers 30
Posts 2774
Boards Moderated 4
Alias Born 10/24/2015

Re: None

Wednesday, 04/22/2020 9:09:19 PM

Wednesday, April 22, 2020 9:09:19 PM

Post# of 77
Small number, but encouraging data on another 'armed' OV*. The full data from cohort one (18 response evaluable patients) should be presented at ASCO. In cohort two they will be testing a triplet (adding Tecentriq). I hope after the PhI RP3 gets tested in a range of 'cold' types, such as pancreatic.

* https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.716
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent REPL News